Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 670 across all filing types
Latest filing 2021-04-19 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司2020年度独董述职报告
Board/Management Information Classification · 95% confidence The document is titled as the "2020年度独立董事述职报告" which translates to "2020 Annual Independent Directors' Work Report." It details the independent directors' qualifications, attendance at board and shareholder meetings, their opinions on key company matters such as use of raised funds, internal controls, accounting policy changes, and overall evaluation of their duties during the year 2020. The content is a detailed report on the independent directors' activities and opinions for the year, which is a form of management or board-related reporting rather than a full annual report or audit report. It is not a simple announcement or certification but a substantive report on board/management information, specifically focusing on independent directors' duties and evaluations. Therefore, the most appropriate classification is Board/Management Information (MANG).
2021-04-19 Chinese
奥锐特药业股份有限公司2020年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '2020年度审计报告' which translates to '2020 Annual Audit Report' for 奥锐特药业股份有限公司. It contains detailed audit opinions, financial statements including consolidated and parent company balance sheets, income statements, cash flow statements, and notes to the financial statements. The content includes auditor's responsibilities, management's responsibilities, key audit matters such as revenue recognition and inventory net realizable value, and detailed financial data. The length is substantial (15,000 characters) and the document is the full audit report, not just an announcement or certification. Therefore, this document fits the category of an Audit Report / Information (AR). FY 2020
2021-04-19 Chinese
奥锐特药业股份有限公司独立董事关于2020年度对外担保情况及关联方占用资金情况的专项说明及独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion from independent directors regarding the company's external guarantees and related party fund occupation for the year 2020. It references regulatory notices and laws related to listed companies and independent directors. The content is a formal attestation about the absence of external guarantees and related party fund occupation during 2020. The document is short (759 characters) and primarily consists of independent directors' opinions and confirmations rather than detailed financial data or audit results. This fits the profile of an Audit Report / Information (AR) as it is a standalone report on specific audit-related matters (external guarantees and related party funds) without being a full annual report or financial statement. Therefore, the classification is AR with high confidence. FY 2020
2021-04-19 Chinese
奥锐特药业股份有限公司2020年年度报告
Annual Report Classification · 100% confidence The document is titled '2020 年年度报告' which translates to '2020 Annual Report'. It contains detailed sections typical of an annual report such as company overview, financial data, management discussion and analysis, risk disclosures, and audit opinions. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes audited financial statements and comprehensive business and financial information for the fiscal year 2020. Therefore, this document fits the definition of an Annual Report (10-K). FY 2020
2021-04-19 Chinese
奥锐特药业股份有限公司关于召开2020年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a notice about the convening of the 2020 Annual General Meeting (AGM) of 奥锐特药业股份有限公司, including details such as the date, voting methods, agenda items, and instructions for shareholders. It does not contain the actual annual report or financial statements but rather informs shareholders about the meeting and the matters to be voted on. The document length is 3418 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2021-04-19 Chinese
奥锐特药业股份有限公司独立董事关于第二届董事会第五次会议相关事项的独立意见
Audit Report / Information Classification · 90% confidence The document is an independent directors' opinion on various matters related to the company's 2020 annual financials, profit distribution plan, use of raised funds, internal control evaluation report, audit firm reappointment, and executive remuneration. It references the 2020 fiscal year and includes opinions on audit reports and financial statements but does not itself contain full financial statements or detailed financial data. The document is a formal opinion letter from independent directors, which is typically part of audit or governance-related disclosures but is not the full annual report or audit report itself. Given the nature of the content focusing on audit opinions and compliance with regulations, and the absence of full financial statements, the best fit is Audit Report / Information (AR). The document length is short (1488 characters), but it contains substantive independent opinions rather than just an announcement or certification, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). FY 2020
2021-04-19 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.